IMPROVER: Involving Men with PROstate cancer in Engaged Research

Dr Antoinette Perry

Prostate cancer is very common in Ireland, affecting one in six men. Dr Antoinette Perry’s research team is developing a better way to detect aggressive prostate cancer from a simple urine test (epiCaPture). Previously, they found that epiCaPture can catch nearly 90% of aggressive prostate cancers.

Now, the team wants to “get outside of our lab” and engage with end-users of this potential new test, doctors, and men living with prostate cancer from across different sectors of Irish society. They want to learn from end-users about their needs and opinions and feed this into epiCaPture development.

 

Relevant References:

Walsh M, Jordan A, Schäfer L, Joha J, Heapes B, Noonan M, Gallagher W, Gallagher H, Manecksha RP, Galvin D, Nason G, Martin T, Lyons C, O’Connor R; UCD Prostate Patient Advisory Committee; Drummond FJ, Kilty C, Perry AS. IMPROVER (Involving Men with Prostate Cancer in Engaged Research): Assessing Patient Experience With Testing, Diagnosis, And Surveillance. Clin Genitourin Cancer. 2024 Mar 4;22(3):102063. doi: 10.1016/j.clgc.2024.102063. Epub ahead of print. PMID: 38537420.

 

 

Back
Start year
2020
End year
2021
Principal Investigator
Dr. Antoinette Perry
Researcher
Dr. Antoinette Perry
Institution
University College Dublin
Grant Funding
IRC New Foundations Grant in partnership with Breakthrough Cancer Research
Linked Breakthrough Research Priorities
2, 6